Aquestive Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Aquestive Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2018 to Q3 2024.
  • Aquestive Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $1.58M, a 104% increase year-over-year.
  • Aquestive Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $5.62M, a 127% increase year-over-year.
  • Aquestive Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2.69M, a 38.6% decline from 2022.
  • Aquestive Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $4.38M, a 35.8% decline from 2021.
  • Aquestive Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $6.82M, a 3.62% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $5.62M $1.58M +$803K +104% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-04
Q2 2024 $4.82M $1.54M +$891K +138% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $3.93M $1.58M +$1.24M +359% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $2.69M $923K +$211K +29.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-05
Q3 2023 $2.48M $774K +$239K +44.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-04
Q2 2023 $2.24M $648K -$1.57M -70.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $3.81M $344K -$569K -62.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $4.38M $712K -$979K -57.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-05
Q3 2022 $5.36M $535K -$1.37M -71.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $6.73M $2.22M +$500K +29.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $6.23M $913K -$594K -39.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-02
Q4 2021 $6.82M $1.69M +$500K +42% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 $6.32M $1.9M +$135K +7.65% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 $6.18M $1.72M -$44K -2.49% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-02
Q1 2021 $6.23M $1.51M -$353K -19% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $6.58M $1.19M -$680K -36.3% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-08
Q3 2020 $7.26M $1.77M -$105K -5.62% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 $7.37M $1.77M -$45K -2.49% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $7.41M $1.86M +$340K +22.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 $7.07M $1.87M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-09
Q3 2019 $1.87M +$634K +51.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 $1.81M -$25.5M -93.4% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 $1.52M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q3 2018 $1.24M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $27.3M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.